Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;41(4):729-732.
doi: 10.1007/s10875-021-00972-1. Epub 2021 Jan 21.

C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19

T M Ayodele Adesanya  1 , Courtney M Campbell  2 , Lijun Cheng  3 , Princess U Ogbogu  4 , Rami Kahwash  2
Affiliations
Review

C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19

T M Ayodele Adesanya et al. J Clin Immunol. 2021 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
C1 esterase inhibitor-related cellular processes and therapeutic targets. a C1 esterase inhibition physiologically regulates the complement, fibrinolytic, and contact systems, all of which may be involved in COVID-19 pathology. SARS-CoV-2 could dysregulate these systems by direct interaction with C1 esterase inhibitor or ACE2 and TMPRSS2. b Multiple medications target C1 esterase inhibitor-related pathways for management of hereditary angioedema, which is caused by C1 esterase inhibitor deficiency or dysfunction. Dash: hypothesized mechanism; HAE, hereditary angioedema; IV, intravenous; SC, subcutaneous; PO, oral
See this image and copyright information in PMC

References

    1. Campbell CM, Kahwash R. Will complement inhibition be the new target in treating COVID-19 related systemic thrombosis? Circulation. 2020;141:1739–1741. doi: 10.1161/CIRCULATIONAHA.120.047419. - DOI - PubMed
    1. Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, Lambris JD. Complement as a target in COVID-19? Nat Rev Immunol. 2020;20:343–344. doi: 10.1038/s41577-020-0320-7. - DOI - PMC - PubMed
    1. Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363–374. doi: 10.1038/s41577-020-0311-8. - DOI - PMC - PubMed
    1. Jiang H, Wagner E, Zhang H, Frank MM. Complement 1 inhibitor is a regulator of the alternative complement pathway. J Exp Med. 2001;194(11):1609–1616. doi: 10.1084/jem.194.11.1609. - DOI - PMC - PubMed
    1. Panagiotou A, Trendelenburg M, Osthoff M. The lectin pathway of complement in myocardial ischemia/reperfusion injury-review of its significance and the potential impact of therapeutic interference by C1 esterase inhibitor. Front Immunol. 2018;9:1151. doi: 10.3389/fimmu.2018.01151. - DOI - PMC - PubMed

MeSH terms

Substances